NATURAL THERAPY FOR DRY EYE

TearSolutions has developed LacripepTM, a proprietary first-in-class peptide therapy

Our mission is to develop a transformative therapy for Dry Eye.

Background

The quality of human tear film is critical for corneal epithelial and neuronal cells’ survival.  Several tear proteins are deficient in different forms of Dry Eye, the most common eye disease. One, called Lacritin, is deficient in ALL forms of Dry Eye and when reintroduced, health is restored.  

Lacripep, which is derived from the Lacritin protein, is a first-in-class topical therapy that preserves all of Lacritin’s bioactivity.

Dry Eye Disease

Dry Eye is an under-diagnosed and under-treated disease that continues to be exacerbated by the following:  

1) increased age, with women being particularly susceptible due to the hormonal changes that occur as they age, 2) environmental factors, such as poor air quality, and 3) staring at computer screens for long periods of time.

Our Solution - Lacripep

TearSolutions’ founder and Chief Scientific Officer, Dr. Gordon Laurie, discovered ‘Lacritin’, a naturally occurring tear protein that is selectively deficient in ALL forms of Dry Eye.  From this discovery, he developed Lacripep, which preserves all of the biological activity of Lacritin in a short stable peptide that can be produced at scale.  Preclinical data showed that, when Lacripep was added topically to eyes of dry eye animals, it restored basal tearing without irritation and healed the corneal surface of the eye.

TearSolutions has now completed a first-in-human Phase I/II trial in primary Sjögren’s Syndrome, who typically have a severe and often debilitating form of Dry Eye and are known to be deficient in Lacritin.  The results showed a rapid improvement, as quickly as two weeks, in corneal health and a reduction in symptoms.

~ 0
Million

people have signs and/or symptoms
of Dry Eye Disease in the United States1

~ 0
Million

people are diagnosed with
Dry Eye Disease in the United States1

~ 0
Billion

people have signs and/or symptoms
of Dry Eye Disease worldwide1

~ 0
Million

people are diagnosed with
Dry Eye Disease worldwide1

The Tear Film

Tear Film instability is one of the main causes of Dry Eye

Mucin Layer
Provides protection of the ocular surface against pathogens, physical damage and stabilizes the tear film, allowing it to spread evenly over the surface of the eye.
 

Produced by corneal epithelial cells and goblet cells on the conjunctiva.

Aqueous Layer

Provides nutrients, enzymes, growth factors, etc. to help nourish the cells of the ocular surface.

Produced by the lacrimal glands.

Lipid Layer

Stabilizes the tear film by complexing with tear proteins to prevent tear film collapse.

Produced by meibomian glands in the eyelids.

Tear Film Instability
Dry Eye
Corneal Disease

Low or no

Lacritin/Lacripep

Corneal Disease

With

Lacritin/Lacripep

Corneal Health

LEADERSHIP TEAM

Experience and expertise in ophthalmology

Gordon W. Laurie, PhD FARVO

Chief Scientific Officer / Co-founder

Marc B. Logan

Executive Chairman / Co-founder

Anil C. Asrani

President / CEO

Colin M. Rolph

Chief Financial Officer

Marc G. Odrich, MD

Chief Medical Officer / Medical Director

Michelle A. Carpenter, JD, RAC

Chief Regulatory Officer

First-in-human Clinical Trial

Goal: Test whether Lacripep restores health to eyes of patients with Primary Sjögren’s Syndrome dry eye (NCT03226444).

Trial Sites: ~35 private and academic clinics in 17 different states.

Status: Enrollment complete.  Statistically significant improvement in both sign and symptom at two weeks.

Phase IIb Clinical Trial

Goal: Optimize Lacripep’s efficacy in patients with moderate/severe general dry eye.  

Trial Sites: ~10 – 12 private and academic clinics expected.

Status:  Clinical trial protocol design/development and fundraising.

TearSolutions, Inc.
315 Old Ivy Way, Suite 301
Charlottesville, Virginia 22903

TearSolutions CFO Colin Rolph:
crolph@tearsolutions.com

434-951-0444

1. Market Scope 2020 Dry Eye Products
Market Report

GET IN TOUCH

2.19.15.GWL (1) (2)

Gordon W. Laurie, PhD FARVO

Dr. Laurie co-founded TearSolutions with Mark Logan in 2013 and serves as Chief Scientific Officer. Dr. Laurie is a Professor of Cell Biology, Biomedical Engineering and Ophthalmology and a former Pinn Scholar at the University of Virginia. He is co-author of the Tear Film Subcommittee of the DEWS II Report, member of the founding Governing Council of the Tear Film and Ocular Surface Society, an Executive Editor of Experimental Eye Research, founder of UVA’s NIH sponsored Biotechnology Training Program (now in its 21st year) and past winner of the Virginia Biotechnology Association Educator of the Year award.
Dr. Laurie’s lab discovered and named ‘lacritin’ out of an unbiased biochemical screen begun in 1992 to address the biological basis of dry eye. Lacripep’ was then created by the Laurie lab as a synthetic peptide embodiment of all known lacritin activities.
placeholder.png

Marc B. Logan

Mr. Logan and Dr. Gordon Laurie co-founded TearSolutions in 2013, and he served as the President and CEO of TearSolutions from 2013 to 2016. Prior to TearSolutions, Mr. Logan was the President, CEO and Chairman of VISX, Inc. (now a division of Johnson & Johnson). VISX invented, developed, obtained FDA approval and commercialized the procedure known as LASIK. Prior to joining VISX, he was Senior VP, COO and served on the Board of Directors of Bausch & Lomb.

anil-asrani-headshot

Anil C. Asrani

Mr. Asrani joined TearSolutions as President and CEO in 2020 after spending more than 9 years with Medtronic PLC, a medical device company where he held positions in marketing, investor relations, business development and strategy. Prior to joining Medtronic, Mr. Asrani lead sales and marketing for Devicix, a medical device design firm, and spent more than a decade performing academic medical research. Early in his career, Mr. Asrani worked in the UVA laboratory of Dr. Gordon Laurie, TearSolutions co-founder and current Chief Scientific Officer, and was an initial investor in TearSolutions.
colin-rolph-headshot

Colin M. Rolph

Colin has been working with startup / early stage companies for the past 20+ years.He is a serial, earlystage CFO and has led numerous companies through all aspects of early stage and growth stage development. Mr. Rolph is also an angel investor and manager of a venture investment fund that focuses on medical devices, biotechnology and IT investments. Mr. Rolph has a B.S. from the Rochester Institute of Technology.
marc-odrich-headshot

Marc G. Odrich, MD

Marc has been in both private and academic medical practice and is currently Associate Professor of Ophthalmology at the University of Virginia where he practices and teaches clinical ophthalmology specializing in Refractive Surgery and Ocular Surface Disease. He has had pivotal roles in the development and commercialization of the excimer laser and the femto laser as former Medical Director for Visx, Inc and currently consults for multiple companies in the areas of corneal and refractive surgery, presbyopia correction and dry eye disease. Marc has authored and run over 25 clinical trials from phase 1 through phase 4 (post market) for industry.
Marc is the Chief Medical Officer for TearSolutions, Inc. a Charlottesville, VA based start up that is in clinical trials with a new drug developed for Sjogrens and dry eye disease. In addition he is a consultant to and Board of Directors member for CXLO, Inc. (epi-on corneal crosslinking for keratoconus), a consultant and medical monitor for Johnson & Johnson’s refractive products, and a consultant to Presbyopia Therapies, LLC.
michelle-carpenter-headshot

Michelle A. Carpenter, JD, RAC

Ms. Carpenter is a senior management leader and regulatory advisor with more than 25 years of experience gaining global approvals for drugs and biologics for companies ranging from start-up to Fortune 500. She has extensive experience in ophthalmology, including multiple programs for dry eye disease (Santen, Otuska) in addition to a broad number of indications to treat anterior and posterior eye segment diseases. Ms. Carpenter has held numerous Senior/Vice President roles in Regulatory Affairs, Quality Affairs and Project Management and has worked at True North and Afferent Pharmaceuticals, Sanofi, Santen, and Merck. She also teaches Regulatory Affairs certification courses for the UC Santa Cruz Bioscience Program and has managed a successful consulting firm.

She earned her Juris Doctorate, with emphasis in Health Law and Ethics, from Golden Gate University and her Bachelor’s degree at University of California at Santa Barbara.